JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target

Benzinga · 10/15 16:16
JMP Securities analyst Silvan Tuerkcan reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform and maintains $70 price target.